<DOC>
	<DOCNO>NCT01822028</DOCNO>
	<brief_summary>Cross-over , tolerability study healthy subject take Zavesca combination Florastor . Forty-two subject randomize one two treatment sequence Zavesca Florastor Zavesca Placebo Florastor . Gastrointestinal tolerability PK endpoint , demographic , laboratory safety testing , AEs SAEs collect throughout seventy-four day study .</brief_summary>
	<brief_title>Two Period / Two Treatment Cross-over Assess Effect Florastor® Gastrointestinal Tolerability , Safety , PK Healthy Subjects Receiving Zavesca®</brief_title>
	<detailed_description>This Phase 1 , single-center , double-blind , randomize , placebo-controlled , two period / two treatment , cross-over study GI tolerability , safety , PK assessment . A total 42 healthy subject enrol . At least 30 % female subject expect enrolled . Subjects participate 2 treatment period ( Treatment Period 1 Treatment Period 2 ) , separate 10- 14-day washout . Subjects randomly allocate treatment sequence , A-B B-A : - Treatment A : Placebo S. boulardii 500 mg twice day ( b.i.d . ) Day 1 Day 16 treatment period , miglustat capsule 100 mg t.i.d . Day 3 Day 16 . - Treatment B : S. boulardii 500 mg b.i.d . Day 1 Day 16 treatment period , miglustat capsule 100 mg t.i.d . Day 3 Day 16 . To minimize possible carry-over effect , 10 14-day washout period add Treatment Period 1 Period 2 . Steady-state PK evaluation occur end Period 1 Period 2 require full-day clinic stay subject . The plan study duration per subject approximately 46 day ( inclusive Screening serious adverse event [ SAE ] follow-up period ) . However , duration may 53 day visit windows utilized . The Screening period may last 30 day prior first administration study medication . Telephone follow-up occur within 48-72 hour last study drug dose treatment period record SAEs/AEs concomitant medication . In addition , subject follow 30 day permanent study drug discontinuation ongoing AEs new SAEs via telephone consult .</detailed_description>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Miglustat</mesh_term>
	<mesh_term>1-Deoxynojirimycin</mesh_term>
	<criteria>Signed informed consent prior studymandated procedure Healthy male female subject age 18 55 year ( inclusive ) Screening Women must negative serum pregnancy test Screening negative urine pregnancy test first day treatment period must use reliable method contraception Screening entire study 30 day last dose . Male subject must agree use reliable contraception throughout study 4 month study drug discontinuation Reliable method contraception subject include follow : Barrier type device ( e.g. , male female condom , diaphragm contraceptive sponge ) use ONLY combination spermicide Intrauterine device Oral contraceptive agent DepoProvera ( medroxyprogesterone acetate ) Levonorgestrel implant Abstinence , rhythm method , contraception partner alone NOT reliable method contraception A BMI 18.5 30 kg/m2 ( inclusive ) Screening No clinically significant finding physical examination , laboratory assessment , electrocardiogram ( ECG ) , vital sign Screening Ingestion medication within 7 day prior study enrollment ( Day 1 ) except contraceptive Use antidiarrheal medication within 30 day prior study enrollment ( e.g. , loperamide ) Use oral probiotic supplement S. boulardii within 30 day prior study enrollment Use oral antifungal antibiotic within 8 week prior study enrollment History yeast allergy Current alcohol drug dependence Renal function impairment , ( i.e. , creatinine clearance [ C Cr ] &lt; 70 mL/min/1.73m2 per CockroftGault ) History GI distress include diarrhea ( 2 loose stool per day , 5 day ) within 30 day prior study enrollment History irritable bowel syndrome , inflammatory bowel disease , disease result frequent severe diarrhea Lactose intolerance Subjects specialize diet , include low carbohydrate diet Lactating , pregnant woman woman plan become pregnant course study History neurological disease/symptom , e.g. , convulsion Loss 500 mL blood within 3 month prior Screening Positive result HIV Ag/Ab , HBsAg antiHCV test Positive result HIV serology Screening History clinical evidence alcoholism drug abuse within 3year period prior Screening Excessive caffeine consumption , define &gt; =5 cup coffee day 800mg/day Screening Smoking within 3 month prior Screening inability refrain smoke course study Any circumstance condition , , opinion investigator , may affect full participation study compliance protocol Legal incapacity limit legal capacity Screening Unplanned weight loss define &gt; 5 % within past month &gt; =10 % last 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>diarrhea</keyword>
</DOC>